Clinical Flashcards
Inhibitors of Purine Biosynthesis
Glutamine analogs: block steps 2, 5, and 15; Azaserine
Folate Metabolism Inhibitors: block steps 4 and 10; comp antagonists
–PABA analog: sulfonamide
–folate analog: methotrexate (also affects TMP syn.)
–lack of folate can lead to ancephaly or spina bifidia
Lesch-Nyhan Syndrome
purine overproduction, gout/kidney stones, neural problems, mental retardation, bizarre self-mutilation, X-linked
defective HGPRT
partly defective –> purine overproduction and gout only
ADA def. aka SCID
lack T and B cells, gene therapy
purine nucleoside phosphorylase def.
AR, immunodef., no T cells
allopurinol
inhibits xanthine oxidase, blocks degradation, less uric acid
analog of hypoxanthine
orotic aciduria
I - orotate phosphoribosyltransferase and orotidylate decarboxylase
II - orotidylate decarboxylase
missing 1 or both enz., give them uridine to skip blocked steps
failure to thrive, apathy, mental retardation, repeated infections, megoblastic anemia, abnormal RBCs, excessive excr. of OA, large spleen and heart
5-Fluorouracil Derivatives
inhibits thymidylate synthase
suicide inhibition
F-dUMP and THF can’t detach from enzyme
herpes and pyrimidine nucleoside salvage
herpes caused by a virus, has its own thymidine kinase, target it and don’t mess w/ rest of body
drug: acyclovir
superactive PRPP synthase
purine overproduction and gout
Prader-Willi Syndrome
4 Mb del. on chr.15q
transmitted by father
moderate mental retardation, hypogonadism, sm. hands and feet, obese
Angelman Syndrome
4Mb del. on chr.15q
transmitted by mother
severe mental retardation, seizures, ataxic gait, behavior disorders
Cystic Fibrosis and testing
AR, mutation in CFTR
del. of 3 bases at F508, so mutant gene is shorter by 3 bp; use PCR
ASO probe can also be used to detect mutation of F508
Nuclear Lamina Mutations: interfere w/ lamina assembly
List diseases and any known mutations
Dilated cardiomyopathy; congenital lipodystrophy;
Emery-Dreifuss muscular dystrophy: AD in Lamins A/C, X in emerin
Hutchinson-Gilford Progeria: Lamin A
DNA and drugs
topoisomerase II poisons - stabalizes covalent DNA top. II complex, antitumor
catalytic inhibitors - act on other steps in catalytic cycle; antineoplastic, cardioprotectors, and modulators
mutations in mitochondrial DNA; disease examples
myoclonic ataxia, MERRF, MELAS, Kearns-Sayre
Parkinson’s and LHON in conjunction w/ environmental factors
mitochondria depletion syndromes
- progressive disease affecting children, those treated for HIV-1 and hep.B virus infections, and young adults
- hepatic issues, muscle issues, red flag is multiorgan disturbance
- ex. Alpers, progressive external ophthalmoplegia, ataxia-neuropathy, and aging
Example diseases for mutations in:
mismatch repair
nucleotide-excision repair
MR: HNPCC aka Lynch syndrome
NER: xeroderma pigmentosum
eEF-2/GTP is inhibited by what?
Diphtheria toxin
antibiotic block of initiation
streptomycin - distorts 30S
antibiotic block of elongation (4 sets)
> tetracyclines- blocks A site
chloroamphenicol- inhibits 50S peptidyltransferase - no peptide bond
erythromycin and clindamycin - inhibits movement of ribosome by binding to 50S
puromycin - analog of tyrosinyl-tRNA; enters A site, incorporated into peptide, premature release of polypeptide; inhibits prok. and euk. protein synthesis
Diseases of Protein Misfolding
prion disorders: stim. other proteins to misfold
Alzheimer’s: amyloid plaques
a-1 related emphysema: trypsin and elastase protease inhibitor fails
Cranio-lenticulo-sultural Dysplasia
AR; mutation in SEC23A - part of COPII coated vesiccles that move proteins from ER to Golgi, mutation leads to dilation of ER, defects in cargo loading and budding; delayed ossification in cranial bones, sultural cataracts, facial dysmorphisms, and skeletal defects
Grisceli Syndrome Type II
AR; mutation in RAB27A gene –> loss of Rab27 mRNA and protein products; episodes of uncontrolled lymphocyte activation, hypomelanosis, immunologic abnormalities, neurologic impairment
CEDNIK: Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome
AR; mutation in SNAP29 - defective docking and fusion; microcephaly, neurologic impairment, psychomotor retardation, failure to thrive, facial dysmorphism, palmoplantar keratoderma, and late onset ichthyosis